Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + albumin-bound paclitaxel + lenvatinib
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of QL1706 (iparomlimab and tuvonralimab), albumin-bound paclitaxel, and lenvatinib. QL1706, developed by Qilu Pharmaceutical using the MabPair platform, is a bifunctional antibody product that simultaneously targets the PD-1 and CTLA-4 immune checkpoints to enhance anti-tumor T-cell activity. Albumin-bound paclitaxel (nab-paclitaxel) is a nanoparticle formulation of the chemotherapy agent paclitaxel that inhibits microtubule dynamics, leading to cell cycle arrest. Lenvatinib is an oral multi-target tyrosine kinase inhibitor that blocks VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET, thereby inhibiting angiogenesis and tumor cell proliferation. This triplet regimen is being investigated by Sun Yat-sen University as a second-line treatment for patients with unresectable or metastatic biliary tract cancer, particularly those who have progressed on prior immunotherapy and chemotherapy.
- Brand names
- Iparomlimab and TuvonralimabAbraxane
- Other names
- nab-paclitaxelQL-1706QL1706QL 1706
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))FGFR3 (Fibroblast growth factor receptor 3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on QL1706 + albumin-bound paclitaxel + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + albumin-bound paclitaxel + lenvatinib.